Difference between revisions of "Team:ETH Zurich"
| Line 136: | Line 136: | ||
<section> | <section> | ||
<div class="HP"> | <div class="HP"> | ||
| + | <h1>HUMAN PRACTICES</h1> | ||
<figure class="HP"> | <figure class="HP"> | ||
<img src="https://static.igem.org/mediawiki/2017/4/4a/T--ETH_Zurich--HPlanding.png"> | <img src="https://static.igem.org/mediawiki/2017/4/4a/T--ETH_Zurich--HPlanding.png"> | ||
</figure> | </figure> | ||
| − | |||
| − | |||
<p>We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we | <p>We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we | ||
introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.</p> | introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.</p> | ||
Revision as of 18:09, 29 October 2017
WHY
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects. That's why we invented CATE, the first all-in-one living cancer therapeutic with an integrated two-step safety mechanism.
A living cure to a living disease!
VISION
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home preferentially in tumors.
It features two safety checkpoint mechanisms to ensure only tumor cells are damaged.
CATE is administered intravenously, travels through the blood and colonizes tumors. When enough bacteria have accumulated in the tumor, they make themselves visible and start preparing the cytotoxic payload.
After imaging the tumor with MRI, the doctor can then activate release of the cancer-killing payload.
To achieve all these novel functions, we designed a genetic circuit that is distributed over two de novo synthesized DNA molecules.
All functions were tested and optimized to make the resulting circuit as safe and well-characterized as possible.
ENGINEERING
We increased the understanding of the system's underlying mathematics by simulating the functions with models.
The models were then used to define important questions to clarify in experiments and develop efficient design strategies.
Experimentally, we collected data to support and refine our models and to show that our system works.
ACHIEVEMENTS
We could experimentally confirm the predictions of the models. After testing every function individually, we combined them one after the other in milestone experiments to show the system in action.
We created and characterized new BioBrick parts that are important for the iGEM competition and are freely for the future iGEM teams.
HUMAN PRACTICES
We went beyond the lab and reached out to experts to better understand current technological and safety issues in order to enhance the design of our project. Further, we introduced our project and the field of synthetic biology to the general public and together explored issues related to safety, ethics and sustainability.
TEAM
We are an interdisciplinary team of eight master students of ETH Zürich who compete in the iGEM championship against hundreds of other teams from all over the world.
